Drug profile · INN
coronavirus modified uridine rna vaccine (sars-cov-2) (active ingredients: tozinameran and riltozinameran)
COMIRNATY RTU (NOTE 2) (BIVALENT, ORIGINAL/OMICRON BA.1) PARTIAL CHANGE APPROVAL
- Patents linked
- 0
- News articles
- 0
Quick answer
coronavirus modified uridine rna vaccine (sars-cov-2) (active ingredients: tozinameran and riltozinameran) (COMIRNATY RTU (NOTE 2) (BIVALENT, ORIGINAL/OMICRON BA.1) PARTIAL CHANGE APPROVAL) is an FDA-listed pharmaceutical active ingredient.
Key facts
Frequently asked questions
What is coronavirus modified uridine rna vaccine (sars-cov-2) (active ingredients: tozinameran and riltozinameran)?
coronavirus modified uridine rna vaccine (sars-cov-2) (active ingredients: tozinameran and riltozinameran) (COMIRNATY RTU (NOTE 2) (BIVALENT, ORIGINAL/OMICRON BA.1) PARTIAL CHANGE APPROVAL) is an FDA-listed pharmaceutical active ingredient.
What is the brand name for coronavirus modified uridine rna vaccine (sars-cov-2) (active ingredients: tozinameran and riltozinameran)?
COMIRNATY RTU (NOTE 2) (BIVALENT, ORIGINAL/OMICRON BA.1) PARTIAL CHANGE APPROVAL is a marketed brand name for coronavirus modified uridine rna vaccine (sars-cov-2) (active ingredients: tozinameran and riltozinameran). Check FDA Drugs@FDA for the current US label holder and prescribing information.